verapamil has been researched along with Arteriosclerosis, Coronary in 49 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In INternational VErapamil-trandolapril STudy, 22,576 CAD patients with hypertension (mean age 66 years) were randomized to verapamil-SR or atenolol-based strategies and followed for 2." | 9.14 | Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. ( Bangalore, S; Champion, A; Franklin, SS; Mancia, G; Messerli, FH; Pepine, CJ, 2009) |
| "Nicorandil with vasodilator effects by a dual mechanism was effective as the cocktail in preventing radial artery spasm during transradial coronary angiography." | 9.12 | Comparative study of nicorandil and a spasmolytic cocktail in preventing radial artery spasm during transradial coronary angiography. ( Cheon, WS; Cho, GY; Choi, YJ; Kim, EJ; Kim, MK; Kim, SH; Park, WJ; Rhim, CY, 2007) |
| " We retrospectively analyzed the International Verapamil SR-Trandolapril Study, which randomized coronary artery disease patients with hypertension to either verapamil SR- or atenolol-based treatment strategies, focusing on characteristics and outcomes of 6166 previously revascularized patients compared with 16 410 nonrevascularized patients." | 7.75 | Characteristics and outcomes of revascularized patients with hypertension: an international verapamil SR-trandolapril substudy. ( Aranda, JM; Champion, A; Cooper-Dehoff, RM; Denardo, SJ; Gaxiola, E; Gong, Y; Handberg, EM; Messerli, FH; Pepine, CJ; Zhou, Q, 2009) |
| "Angina and hypertension are common in patients with coronary artery disease (CAD); however, the effect on mortality is unclear." | 6.78 | Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST). ( Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Pepine, CJ; Winchester, DE, 2013) |
| "Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment." | 6.71 | A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. ( Bakris, GL; Bristol, HA; Cangiano, JL; Cohen, JD; Cooper-DeHoff, RM; Erdine, S; Garcia-Barreto, D; Handberg, EM; Keltai, M; Kolb, HR; Kowey, P; Mancia, G; Marks, RG; Messerli, FH; Parmley, WW; Pepine, CJ, 2003) |
| "We utilized data from 22,576 hypertensive coronary artery disease patients, prospectively enrolled in the INternational VErapamil-Trandolapril STudy (INVEST)." | 5.16 | Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy. ( Brumback, BA; Cooper-Dehoff, RM; Delaney, JA; Gerhard, T; Johnson, JA; Pepine, CJ; Shuster, J; Winterstein, AG, 2012) |
| "In INternational VErapamil-trandolapril STudy, 22,576 CAD patients with hypertension (mean age 66 years) were randomized to verapamil-SR or atenolol-based strategies and followed for 2." | 5.14 | Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. ( Bangalore, S; Champion, A; Franklin, SS; Mancia, G; Messerli, FH; Pepine, CJ, 2009) |
| " Statistical modeling from INVEST (INternational VErapamil-Trandolapril STudy), suggests an association between dual and triple therapy and decreased risk of primary outcome ([PO] first occurrence of death, nonfatal MI, or nonfatal stroke) in patients with hypertension and coronary artery disease (CAD)." | 5.12 | Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers. ( Bakris, GL; Champion, A; Cooper-Dehoff, RM; Kupfer, S; Pepine, CJ; Zhou, Q, 2007) |
| "When antihypertensive treatment options are clinically equivalent, prescribers may first consider using a verapamil SR-based strategy, especially in patients with CAD who have no history of depression." | 5.12 | Depressive symptoms in coronary artery disease patients after hypertension treatment. ( Lopez, LM; Pepine, CJ; Ried, LD; Sauer, BC; Taylor, MD; Tueth, MJ, 2006) |
| "Nicorandil with vasodilator effects by a dual mechanism was effective as the cocktail in preventing radial artery spasm during transradial coronary angiography." | 5.12 | Comparative study of nicorandil and a spasmolytic cocktail in preventing radial artery spasm during transradial coronary angiography. ( Cheon, WS; Cho, GY; Choi, YJ; Kim, EJ; Kim, MK; Kim, SH; Park, WJ; Rhim, CY, 2007) |
| " Therapeutic response to the angiotensin-converting enzyme inhibitor trandolapril used as add-on therapy to stable calcium channel blocker therapy with verapamil sustained release 240 mg was addressed in a racially/ethnically diverse group of 1,832 hypertensive patients with coronary artery disease." | 5.12 | Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). ( Brunner, M; Cooper-DeHoff, RM; Gong, Y; Johnson, JA; Karnes, JH; Langaee, TY; Pepine, CJ, 2007) |
| "In the Angina Prognosis Study in Stockholm (APSIS), 809 patients with stable angina pectoris were studied prospectively during double-blind treatment with verapamil or metoprolol." | 5.09 | Prognostic implications of intima-media thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris. ( Björkander, I; Eriksson, SV; Forslund, L; Held, C; Hjemdahl, P; Rehnqvist, N, 2001) |
| "The US cohort of the International Verapamil SR-Trandolapril Study (INVEST), a randomized clinical trial of 16 688 patients aged 50 years or older with hypertension and coronary artery disease, was conducted between September 2, 1997, and December 15, 2000, with in-trial follow-up through February 14, 2003." | 4.02 | Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial. ( Cooper-DeHoff, RM; Dasa, O; Gong, Y; Handberg, E; Howard, G; Pepine, CJ; Smith, SM, 2021) |
| " James Women Take Heart (WTH; women without coronary disease at baseline), Women's Ischemia Syndrome Evaluation (women with signs/symptoms of ischemia at baseline), and the INternational VErapamil-Trandolapril STudy (INVEST; women with coronary artery disease and hypertension at baseline), totaling 15,108 adult women with no hypertension, non-RH (blood pressure [BP] ≥140/90 mmHg on ≤2 drugs or BP <140/90 mmHg on 1-3 drugs), or aRH (BP ≥140/90 mmHg on ≥3 drugs or anyone on ≥4 drugs) at baseline." | 3.83 | Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease. ( Cooper-DeHoff, RM; Gong, Y; Gulati, M; Handberg, E; Huo, T; Merz, CN; Pepine, CJ; Smith, SM, 2016) |
| " Metabolic dysregulation is a major contributor to coronary disease; therefore, we assessed LXRA in International Verapamil Sustained Release SR Trandolapril Study Genetic Substudy (INVEST-GENES), a genetic-substudy of a large clinical trial in patients with hypertension and coronary artery disease." | 3.77 | Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study. ( Cooper-DeHoff, RM; Johnson, JA; Martin, MA; Pacanowski, MA; Pepine, CJ; Price, ET; Zineh, I, 2011) |
| "This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary artery disease." | 3.77 | Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. ( Bavry, AA; Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Khaliq, A; Pepine, CJ, 2011) |
| " We retrospectively analyzed the International Verapamil SR-Trandolapril Study, which randomized coronary artery disease patients with hypertension to either verapamil SR- or atenolol-based treatment strategies, focusing on characteristics and outcomes of 6166 previously revascularized patients compared with 16 410 nonrevascularized patients." | 3.75 | Characteristics and outcomes of revascularized patients with hypertension: an international verapamil SR-trandolapril substudy. ( Aranda, JM; Champion, A; Cooper-Dehoff, RM; Denardo, SJ; Gaxiola, E; Gong, Y; Handberg, EM; Messerli, FH; Pepine, CJ; Zhou, Q, 2009) |
| "7-year follow-up, compared a calcium antagonist-led strategy (verapamil SR plus trandolapril) with a beta-blocker-led strategy (atenolol plus hydrochlorothiazide) for hypertension treatment and prevention of cardiovascular outcomes in coronary artery disease patients." | 3.75 | INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. ( Champion, A; Cooper-DeHoff, RM; Handberg, EM; Legler, UF; Mancia, G; Pepine, CJ; Zhou, Q, 2009) |
| "Angina and hypertension are common in patients with coronary artery disease (CAD); however, the effect on mortality is unclear." | 2.78 | Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST). ( Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Pepine, CJ; Winchester, DE, 2013) |
| "Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment." | 2.71 | A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. ( Bakris, GL; Bristol, HA; Cangiano, JL; Cohen, JD; Cooper-DeHoff, RM; Erdine, S; Garcia-Barreto, D; Handberg, EM; Keltai, M; Kolb, HR; Kowey, P; Mancia, G; Marks, RG; Messerli, FH; Parmley, WW; Pepine, CJ, 2003) |
| "or placebo." | 2.67 | Retardation of development and progression of coronary atherosclerosis: a new indication for calcium antagonists? ( Alle, M; Cieslinski, G; Kaltenbach, M; Kober, G; Noack, H; Reifart, N; Roebruck, P; Schneider, W, 1990) |
| "Untreated hypertension has a variety of serious consequences, such as stroke, congestive heart failure and coronary heart disease, the incidences of which escalate sharply in the presence of other risk factors." | 2.38 | Primary prevention potential of the calcium antagonists. Effects on blood pressure and lipid pattern. ( Midtbø, K, 1992) |
| "We report on a 46-year-old male with unstable angina pectoris due to a total proximal occlusion of the left circumflex artery." | 1.30 | [Anti-ischemic effect of verapamil within the scope of interventional recanalization]. ( Baumgart, D; Caspari, G; Eggebrecht, H; Erbel, R; Haude, M; Oldenburg, O; Schaar, J, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (10.20) | 18.7374 |
| 1990's | 4 (8.16) | 18.2507 |
| 2000's | 24 (48.98) | 29.6817 |
| 2010's | 13 (26.53) | 24.3611 |
| 2020's | 3 (6.12) | 2.80 |
| Authors | Studies |
|---|---|
| Sava, RI | 1 |
| Chen, YE | 1 |
| Smith, SM | 4 |
| Gong, Y | 13 |
| Cooper-DeHoff, RM | 23 |
| Keeley, EC | 1 |
| Pepine, CJ | 28 |
| Handberg, EM | 10 |
| Scantlebury, DC | 1 |
| Morris, RL | 1 |
| Dasa, O | 1 |
| Howard, G | 1 |
| Handberg, E | 3 |
| Wokhlu, A | 1 |
| Elgendy, IY | 2 |
| Bavry, AA | 4 |
| McDonough, CW | 1 |
| Padmanabhan, S | 1 |
| Burkley, B | 1 |
| Langaee, TY | 3 |
| Melander, O | 1 |
| Dominiczak, AF | 1 |
| Johnson, JA | 7 |
| Winchester, DE | 1 |
| Hizoh, I | 1 |
| Majoros, Z | 1 |
| Major, L | 1 |
| Gulyas, Z | 1 |
| Szabo, G | 1 |
| Kerecsen, G | 1 |
| Korda, A | 1 |
| Molnar, F | 1 |
| Kiss, RG | 1 |
| Denardo, SJ | 2 |
| Farsang, C | 1 |
| Keltai, M | 2 |
| Szirmai, L | 1 |
| Messerli, FH | 9 |
| Mancia, G | 7 |
| Grant, EK | 1 |
| Berul, CI | 1 |
| Huo, T | 1 |
| Gulati, M | 1 |
| Merz, CN | 1 |
| Gaxiola, E | 3 |
| Aranda, JM | 1 |
| Champion, A | 7 |
| Zhou, Q | 5 |
| Björkander, I | 2 |
| Forslund, L | 2 |
| Ericson, M | 1 |
| Rehnqvist, N | 2 |
| Hjemdahl, P | 2 |
| Kahan, T | 1 |
| Bangalore, S | 2 |
| Franklin, SS | 1 |
| Pacanowski, MA | 2 |
| Zineh, I | 3 |
| Gerhard, T | 2 |
| Ried, LD | 2 |
| Bakris, GL | 4 |
| Kupfer, S | 4 |
| Legler, UF | 1 |
| Weber, MA | 1 |
| Price, ET | 1 |
| Martin, MA | 1 |
| Khaliq, A | 1 |
| Delaney, JA | 1 |
| Shuster, J | 1 |
| Brumback, BA | 1 |
| Winterstein, AG | 1 |
| Vandell, AG | 1 |
| Lobmeyer, MT | 1 |
| Gawronski, BE | 1 |
| Gums, JG | 1 |
| Beitelshees, AL | 1 |
| Turner, ST | 1 |
| Chapman, AB | 1 |
| Bailey, KR | 1 |
| Boerwinkle, E | 1 |
| Liggett, SB | 1 |
| TSCHIRDEWAHN, B | 1 |
| KLEPZIG, H | 1 |
| STRAESSLE, B | 1 |
| BURCKHARDT, D | 1 |
| FISCHER, K | 1 |
| Pasquetto, G | 1 |
| Reimers, B | 1 |
| Favero, L | 1 |
| Saccà, S | 1 |
| Cernetti, C | 1 |
| Napodano, M | 1 |
| Piccolo, P | 1 |
| Pascotto, P | 1 |
| Marks, RG | 1 |
| Kowey, P | 1 |
| Cangiano, JL | 1 |
| Garcia-Barreto, D | 1 |
| Erdine, S | 3 |
| Bristol, HA | 1 |
| Kolb, HR | 1 |
| Cohen, JD | 2 |
| Parmley, WW | 1 |
| Yu, XC | 1 |
| Wu, S | 1 |
| Chen, CF | 1 |
| Pang, KT | 1 |
| Wong, TM | 1 |
| Flack, JM | 1 |
| Bestehorn, HP | 1 |
| Neumann, FJ | 1 |
| Büttner, HJ | 1 |
| Betz, P | 1 |
| Stürzenhofecker, P | 1 |
| von Hodenberg, E | 1 |
| Verdun, A | 1 |
| Levai, L | 1 |
| Monassier, JP | 1 |
| Roskamm, H | 1 |
| Cooper-DeHoff, R | 2 |
| Wessel, TR | 1 |
| Arant, CB | 1 |
| Sleight, P | 2 |
| Geiser, EA | 1 |
| Kowey, PR | 1 |
| Kolloch, RE | 1 |
| Benetos, A | 3 |
| Coca, A | 2 |
| Conti, CR | 2 |
| Hewkin, AC | 3 |
| Tavazzi, L | 1 |
| Tueth, MJ | 1 |
| Taylor, MD | 1 |
| Sauer, BC | 1 |
| Lopez, LM | 1 |
| Kolloch, R | 1 |
| Kim, SH | 1 |
| Kim, EJ | 1 |
| Cheon, WS | 1 |
| Kim, MK | 1 |
| Park, WJ | 1 |
| Cho, GY | 1 |
| Choi, YJ | 1 |
| Rhim, CY | 1 |
| Brunner, M | 1 |
| Karnes, JH | 1 |
| Uretsky, S | 1 |
| Matsuo, H | 1 |
| Watanabe, S | 1 |
| Watanabe, T | 1 |
| Warita, S | 1 |
| Kojima, T | 1 |
| Hirose, T | 1 |
| Iwama, M | 1 |
| Ono, K | 1 |
| Takahashi, H | 1 |
| Segawa, T | 1 |
| Minatoguchi, S | 1 |
| Fujiwara, H | 1 |
| Oldenburg, O | 1 |
| Baumgart, D | 1 |
| Schaar, J | 1 |
| Eggebrecht, H | 1 |
| Caspari, G | 1 |
| Haude, M | 1 |
| Erbel, R | 1 |
| Held, C | 1 |
| Eriksson, SV | 1 |
| Midtbø, K | 1 |
| Ram, CV | 1 |
| Schneider, W | 2 |
| Kober, G | 2 |
| Roebruck, P | 1 |
| Noack, H | 1 |
| Alle, M | 1 |
| Cieslinski, G | 1 |
| Reifart, N | 1 |
| Kaltenbach, M | 2 |
| Winniford, MD | 1 |
| Jansen, DE | 1 |
| Reynolds, GA | 1 |
| Apprill, P | 1 |
| Black, WH | 1 |
| Hillis, LD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| Omission of Prophylactic Verapamil Use in Transradial Coronary Interventions[NCT01402427] | 591 participants (Actual) | Interventional | 2011-03-31 | Completed | |||
| Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519] | Phase 4 | 1,701 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)[NCT04545151] | Phase 2 | 138 participants (Anticipated) | Interventional | 2021-02-08 | Recruiting | ||
| Evaluation of the Efficacy of Natural Senolytic Agents and NLRP3 Inhibitors in Treatment of Osteoarthritis: Randomized, Double Blinded ,Placebo Controlled Trial[NCT05276895] | 60 participants (Anticipated) | Interventional | 2022-07-01 | Suspended (stopped due to unavailability of drugs) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01402427)
Timeframe: The amount of contrast medium will be assessed within 1 minute after completion of coronary angiography or intervention.
| Intervention | milliliter (Median) |
|---|---|
| Verapamil | 75.0 |
| Placebo | 72.5 |
(NCT01402427)
Timeframe: Fluoroscopic time will be assessed within 1 minute after completion of coronary angiography or intervention.
| Intervention | minutes (Median) |
|---|---|
| Verapamil | 4.8 |
| Placebo | 4.4 |
(NCT01402427)
Timeframe: Procedural time will be assessed within 1 minute after completion of coronary angiography or intervention.
| Intervention | minutes (Median) |
|---|---|
| Verapamil | 17.0 |
| Placebo | 16.0 |
(NCT01402427)
Timeframe: Occurrence of access site conversion will be assessed within 1 minute after completion of coronary angiography or intervention.
| Intervention | participants (Number) |
|---|---|
| Verapamil | 2 |
| Placebo | 5 |
Code break: a composite of access site conversion and unplanned use of vasodilators. (NCT01402427)
Timeframe: Occurrence of code breaking will be assessed within 1 minute after completion of coronary angiography or intervention.
| Intervention | participants (Number) |
|---|---|
| Verapamil | 4 |
| Placebo | 10 |
(NCT01402427)
Timeframe: Vasodilator use will be assessed within 1 minute after completion of coronary angiography or intervention.
| Intervention | participants (Number) |
|---|---|
| Verapamil | 297 |
| Placebo | 6 |
Analysis of the rates of significant pain defined as pain score ≥4 on a semiquantitative scale ranging from 1 to 6. (NCT01402427)
Timeframe: Subjective pain will be assessed within 1 minute after completion of coronary angiography or intervention.
| Intervention | participants (Number) |
|---|---|
| Verapamil | 26 |
| Placebo | 21 |
(NCT00246519)
Timeframe: baseline to 18 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Atenolol +HCTZ Arm | -12.06 |
| HCTZ + Atenolol | -13.33 |
2 reviews available for verapamil and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Primary prevention potential of the calcium antagonists. Effects on blood pressure and lipid pattern.
Topics: Blood Pressure; Coronary Artery Disease; Humans; Hypertension; Lipids; Verapamil | 1992 |
Anti-atherosclerotic and vasculoprotective actions of calcium antagonists.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Cholesterol; Coronary Artery Disease; Female; Hum | 1990 |
25 trials available for verapamil and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Cardiovasc | 2013 |
Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST).
Topics: Age Factors; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 2013 |
Need for prophylactic application of verapamil in transradial coronary procedures: a randomized trial. The VITRIOL (is Verapamil In TransRadial Interventions OmittabLe?) trial.
Topics: Aged; Arterial Occlusive Diseases; Calcium Channel Blockers; Coronary Artery Disease; Double-Blind M | 2014 |
Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Drug Therapy, Comb | 2015 |
Long-Term Mortality in Hypertensive Patients With Coronary Artery Disease: Results From the US Cohort of the International Verapamil (SR)/Trandolapril Study.
Topics: Aged; Blood Pressure Determination; Cause of Death; Comorbidity; Coronary Artery Disease; Dose-Respo | 2016 |
Long-term stability of heart rate variability in chronic stable angina pectoris, and the impact of an acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Coron | 2009 |
Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Coronary Disease; | 2009 |
Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Female; Humans; Hy | 2009 |
Systolic blood pressure and subjective well-being in patients with coronary artery disease.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Drug Therapy, Comb | 2009 |
Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; A | 2007 |
Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Confounding Factors, Epidemiologic; Coronary Artery D | 2012 |
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2003 |
Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: the randomized, double-blind, placebo-controlled, multicenter Verapamil Slow-Release for Prevention of Cardiovascular Even
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Calcium Channe | 2004 |
Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST).
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Body Mass I | 2005 |
Depressive symptoms in coronary artery disease patients after hypertension treatment.
Topics: Aged; Antihypertensive Agents; Atenolol; Coronary Artery Disease; Depression; Female; Humans; Male; | 2006 |
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cause of Death; Coronary Artery Disease; Di | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Comparative study of nicorandil and a spasmolytic cocktail in preventing radial artery spasm during transradial coronary angiography.
Topics: Coronary Angiography; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Age | 2007 |
Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study).
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2007 |
Obesity paradox in patients with hypertension and coronary artery disease.
Topics: Age Distribution; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Causality; Cohort Studie | 2007 |
Prevention of no-reflow/slow-flow phenomenon during rotational atherectomy--a prospective randomized study comparing intracoronary continuous infusion of verapamil and nicorandil.
Topics: Aged; Atherectomy, Coronary; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Cor | 2007 |
Prognostic implications of intima-media thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris.
Topics: Aged; Angina Pectoris; Arteriosclerosis; Carotid Arteries; Carotid Artery Diseases; Coronary Artery | 2001 |
Anti-atherosclerotic and vasculoprotective actions of calcium antagonists.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Cholesterol; Coronary Artery Disease; Female; Hum | 1990 |
Retardation of development and progression of coronary atherosclerosis: a new indication for calcium antagonists?
Topics: Animals; Coronary Artery Bypass; Coronary Artery Disease; Diet, Atherogenic; Diltiazem; Female; Huma | 1990 |
Can the progression of coronary sclerosis be influenced by calcium antagonists?
Topics: Angiocardiography; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Artery Disease; Doub | 1989 |
23 other studies available for verapamil and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The INternational VErapamil SR-Trandolapril STudy (INVEST).
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Cha | 2020 |
Hypertension and Coronary Artery Disease in Women: Is Aggressive Blood Pressure Control Appropriate?
Topics: Blood Pressure; Coronary Artery Disease; Female; Humans; Hypertension; Indoles; Verapamil | 2020 |
Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Coronary Artery Disease; Female; Humans; Hy | 2021 |
Mortality implications of lower DBP with lower achieved systolic pressures in coronary artery disease: long-term mortality results from the INternational VErapamil-trandolapril STudy US cohort.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Coronary Artery Disease; Diastole; | 2018 |
Ablation of ventricular arrhythmia originating from the aortic sinus of Valsalva in an adolescent with anomalous origin of the right coronary artery.
Topics: Adolescent; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Catheter Ablation; Coronary Angiography; C | 2016 |
Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Artery Disease; Drug Resistance; Fema | 2016 |
Characteristics and outcomes of revascularized patients with hypertension: an international verapamil SR-trandolapril substudy.
Topics: Aged; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Blood Pressure; Calcium Channel Block | 2009 |
INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Coro | 2009 |
Hypertension: BP reduction in patients with diabetes--uncertainties remain.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers; Coronary Artery Disease | 2010 |
Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study.
Topics: Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Channel Blockers; Case-Control Stu | 2011 |
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celec | 2011 |
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Bloc | 2012 |
[CLINICAL STUDY OF THE EFFECT OF ISOPTIN AND ISOPTIN S IN PATIENTS WITH CORONARY INSUFFICIENCY].
Topics: Coronary Artery Disease; Coronary Disease; Cyanides; Humans; Vasodilator Agents; Verapamil | 1963 |
[ISOPTIN (D-365), CLINICAL STUDIES ON THE TREATMENT OF CORONARY HEART DISEASE].
Topics: Anti-Arrhythmia Agents; Biomedical Research; Coronary Artery Disease; Coronary Disease; Humans; Vaso | 1965 |
[DRUG THERAPY OF CORONARY INSUFFICIENCY].
Topics: Anti-Arrhythmia Agents; Coronary Artery Disease; Coronary Disease; Humans; Myocardial Infarction; Ve | 1965 |
Distal filter protection during percutaneous coronary intervention in native coronary arteries and saphenous vein grafts in patients with acute coronary syndromes.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Balloon Occlusion; Biomarkers; Blood Vessel Pro | 2003 |
Antihypertensive and anti-arrhythmic effects of an extract of Radix Stephaniae Tetrandrae in the rat.
Topics: Alkaloids; Animals; Arrhythmias, Cardiac; Arterial Occlusive Diseases; Benzylisoquinolines; Calcium | 2004 |
Calcium antagonist strategies for coronary artery disease.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Coronary Artery Disease; Diastole | 2004 |
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2004 |
Predictors of adverse outcome among patients with hypertension and coronary artery disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium | 2006 |
Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Black People; Coronary Artery Disease; D | 2008 |
[Anti-ischemic effect of verapamil within the scope of interventional recanalization].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Blood Flow Velocity; Calcium Channel Blockers; Cor | 1999 |
Cigarette smoking-induced coronary vasoconstriction in atherosclerotic coronary artery disease and prevention by calcium antagonists and nitroglycerin.
Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Cardiac Pacing, Artificial; Coronary Artery D | 1987 |